• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
【24h】

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.

机译：Bupropion和Naltrexone：对其单独使用的审查以及组合用于治疗肥胖症。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Bupropion and naltrexone are centrally active drugs that have shown potential efficacy - alone and in combination - for the treatment of obesity. OBJECTIVE: To explore the efficacy and safety of naltrexone and bupropion alone and in a novel combination drug that utilizes sustained-release (SR) formulations of both drugs and to evaluate their efficacy in promoting weight loss. The mechanisms of action of these centrally acting drugs are discussed. Preclinical and clinical studies of bupropion and naltrexone alone and in combination are reviewed. RESULTS/CONCLUSIONS: Both bupropion and naltrexone have been shown individually to induce weight loss. Bupropion has greater efficacy as monotherapy. Naltrexone SR potentiates the effects of bupropion SR; thus, this synergistic combination has the potential for additional weight loss compared to monotherapy. Current Phase III trials will yield further safety and efficacy information regarding these drugs in combination.
机译：背景：Bupropion和Naltrexone是中央活性药物，其仅示出了潜在的疗效 - 单独和组合 - 用于治疗肥胖症。 目的：仅探讨单独的纳曲酮和中产能的疗效和安全性，并以一种利用两种药物的缓释（SR）制剂的新型组合药物，并评估它们在促进体重减轻时的功效。 讨论了这些中央作用药物的作用机制。 综述了单独的Bulopion和Naltrexone和组合的临床前和临床研究。 结果/结论：Bupropion和Naltrexone都单独显示以引起体重减轻。 Bupropion具有更高的疗效作为单药治疗。 纳曲酮SR强调了Bupropion SR的影响; 因此，与单疗法相比，这种协同组合具有额外的体重减轻的可能性。 目前的第三阶段试验将产生关于这些药物的进一步安全性和有效信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号